More intriguingly, Klotho and fibroblast growth factor-23 (FGF-23) axis is known to be trivial to the development of complications of the CKD including VC, where inhibition of FGF23 signaling and/or OGT/O-GlcNAc has been found to reverse the elevated O-GlcNAc modification of proteins, downstream activation of nuclear factor of activated T-cells, and release of interleukin-6 (Krick et al., 2018a,b). This evidence concerns the gene IL6 and chronic kidney disease.